Blog

30.7% (n=35) subjects exhibited autoimmunity, superseding previously reported percentages of autoimmunity in NVP-AEW541 the Rabbit Polyclonal to PIAS2 general CVID population across the United States (8,25,26). Keywords:CVID, gastrointestinal, noninfectious, infectious, enteropathy == Introduction == Common Variable Immunodeficiency (CVID) is usually a heterogenous spectrum of genetic conditions leading to low or absent immunoglobulins, increased susceptibility to sinopulmonary infections, and for some, evidence of autoimmunity and increased risk of lymphoproliferative disorders. As a byproduct of B cell dysfunction, laboratory hallmarks of CVID include low IgG with concomitant low IgM and/or IgA, poor antibody responses following vaccination, markedly decreased isotype switched memory B cells (CD27+IgD-IgM+), and growth of anergic B cells (CD21Low) (1). T cell defects have also been explained in CVID including aberrant cytokine expression, low numbers of CD4 and CD8 T cells, and diminished NVP-AEW541 cell proliferation (2,3). Standard treatment entails administration of subcutaneous or intravenous immunoglobulin replacement therapy, which is generally efficacious and well tolerated. However, gastrointestinal (GI) manifestations of this immune defect are often debilitating, notoriously hard to treat and contribute to heightened morbidity and mortality in patients with CVID. Prevalence rates of GI complications in CVID have varied considerably. In a large study examining data on 2,212 patients from 28 medical centers contributing to the European Society for Immunodeficiencies Database, 77 of 901 patients (9%) were afflicted with enteropathy but the range for numerous centers was between 0 to 21% (4). However, gastrointestinal disease, both infectious and noninfectious in etiology, is one of the most universally cited complications in patients with CVID, and the range of GI pathology is usually vast. In our previous cohort of 473 patients with CVID NVP-AEW541 analyzed over four decades, approximately 15.4% of patients experienced GI complications, including 5.9% with malabsorption, 4.2% with inflammatory bowel disease and 9.1% with liver disease such as hepatitis or hepatic granulomas (5). In this article, we describe the 114 patients who experienced GI disease from our current cohort of 728 CVID patients evaluated at the Mount Sinai Hospital, a quaternary-care academic center in New York City. We also discuss the recent literature on CVID related GI disease, including diagnosis and management of infectious and noninfectious sequela and the range of genetic defects implicated in CVID related GI disease. == Methods == == Clinical and demographic information for CVID subjects == A retrospective chart analysis was conducted to characterize clinical and demographic information for 114 subjects with CVID associated GI disease. The data were collectedviamedical records as previously explained from the current total cohort of 728 subjects (15.6%) (5). Subjects were evaluated at 1 of 2 centers, either the Immune Deficiency Clinic at The Mount Sinai Hospital or earlier at the Memorial Sloan-Kettering Malignancy Center in New York City, New York. Demographic information including age, and sex were gathered from electronic medical records. The age of patients is usually given based on the year of birth. Subjects were confirmed to have CVID based on general consensus and previously published guidelines (1,6). Confirmation of CVID required a significant decrease of IgG, of at least two standard deviations below the mean based on age, with concurrent decrease in either IgA and/or IgM for the vast majority of patients. Poor antibody responses to vaccination, initiation of symptoms after the age of 2, as well as exclusion of other identified causes of hypogammaglobulinemia supported NVP-AEW541 the diagnosis of CVID (1). Disease onset is more difficult to define, but we used the first documented description of symptoms likely to be associated with CVID, such as recurrent sinopulmonary infections, or autoimmunity. The GI cohort explained here includes only those patients where GI disease predominated as the most common complaint over time, based on chart review. Immunoglobulin levels were collected prior to initiation of immunoglobulin replacement therapy in order to establish a baseline. All immunoglobulin levels that were below the quantitative assays lower limit of detection were converted to zero (i.e., an IgA level <5 mg/dL was changed to 0 mg/dL) for purposes of appropriate statistical analysis. Further immunologic characterization included phenotypic circulation cytometry capturing numbers of total peripheral T cells, CD4+, and CD8+ T cells and IgMIgDCD27+isotype switched memory B cells as a proportion of total peripheral B cells. GI disease was diagnosed by clinical history,.